How to think about CDMO stocks (and avoid chasing every buzzword)

If you follow pharma or healthcare stocks at all, you’ve probably seen the term “CDMO” everywhere lately. It’s become one of those market buzzwords that shows up in every investor presentation and stock pitch.

The problem: not every company calling itself a CDMO is actually doing the kind of work investors are paying up for. Some are true development partners to global pharma. Others are basically just manufacturers with a new label.

In this guide, I want to walk through what CDMOs really do, how they’re different from plain contract manufacturers, and a simple way to think about “tiers” of CDMO businesses so you’re not just chasing the trend with no framework.

What a CDMO actually does

Let’s start with the basics. CDMO stands for Contract Development and Manufacturing Organization.

Imagine a biotech company discovers a promising new drug. They understand the science, but they may not have the expertise or infrastructure to turn that lab molecule into something that can be made safely and consistently at scale.

They need help answering questions like:

• How do we manufacture this molecule efficiently?
• How do we make the process stable and reproducible?
• How do we scale from lab batches to clinical trial batches to commercial scale?
• How do we handle all the analytical, regulatory, and tech transfer work along the way?

This is where a CDMO comes in. A true CDMO doesn’t just run a factory. It works with the customer through the development journey and then, if things go well, continues into commercial manufacturing.

Typical CDMO capabilities include:

• Process development (figuring out how to make the molecule reliably)
• Formulation development (turning the molecule into a usable drug form)
• Analytical development and testing
• Scale-up from lab to pilot to full scale
• Technology transfer between sites
• Regulatory support
• Commercial manufacturing once the drug is approved

So the relationship can start when the molecule is still experimental and continue for years if the drug makes it to market.

How a CDMO differs from a CMO

Now compare this with a CMO: a Contract Manufacturing Organization.

With a CMO, the customer already has:

• A defined product
• A mature manufacturing process
• Established specifications

The CMO’s job is mainly to provide capacity and execute that existing process. In other words:

• CMO = mostly manufacturing
• CDMO = development + manufacturing

This difference is more than just semantics. It changes the economics and the stickiness of the relationship.

With a CMO, the relationship can be more transactional. Customers can compare suppliers on:

• Cost
• Capacity
• Quality and reliability

With a CDMO that has helped develop the process, scale it up, and supply clinical material, the relationship is much harder to switch. The CDMO has:

• Deep, molecule-specific know-how
• Data and experience regulators care about
• Established systems and documentation around that product

Moving to a new partner often means:

• Time-consuming tech transfer
• New validation work
• Regulatory filings and approvals
• Operational risk

That’s why investors get excited about true CDMO models: you’re not just selling capacity, you’re embedding yourself into the customer’s drug program for potentially many years.

The key investor question: when does the company enter the journey?

When you look at a so-called CDMO stock, the first question to ask is:

At what stage does this company enter the customer’s journey?

Let’s compare two simplified examples:

Company A
• Gets large orders to manufacture an already commercialized API
• Customer provides most of the process and specs
• Company A mainly provides capacity and execution

Company B
• Works with pharma/biotech while the molecule is still in development
• Helps with process development and scale-up
• Produces clinical trial batches
• Has the opportunity to manufacture commercially if the drug succeeds

Both might report “contract manufacturing” revenue. Both might use the CDMO label. But they are not the same investment story.

Company B has something Company A doesn’t: a development pipeline of molecules that could turn into high-value commercial contracts later on.

What to look for beyond the CDMO label

Here are four practical questions I’d ask about any company calling itself a CDMO:

1. When do they get involved?

• Only after the product is commercialized? That looks more like a CMO/contract manufacturer.
• During development (pre-clinical or clinical), with the ability to take the molecule all the way to commercial? That’s closer to a true CDMO.

2. What capabilities do they actually have?

Look for evidence of capabilities beyond basic manufacturing:

• Process development
• Formulation development
• Analytical method development
• Scale-up and tech transfer
• Regulatory support
• Ability to handle complex chemistry or modalities (peptides, biologics, ADCs, etc.)

The more of these they have in-house, the more deeply they can embed with customers.

3. Do development projects convert into commercial revenue?

A development project might start small in revenue terms, but if the molecule succeeds in trials and gets approved, that same project can become a long-term commercial contract.

So I’d ask:

• How many molecules have they taken from development into commercial supply?
• How many commercial molecules are they currently supplying?
• What does the pipeline look like by phase (early, late-stage, commercial)?

This is where you start to see whether the company has a real engine for future revenue, or just a bunch of one-off projects.

4. How much of the business is truly CDMO?

Some companies have a large base business (like branded generics or APIs) and a small CDMO division on the side.

That doesn’t make them “CDMO plays” in the way the market often talks about them. It just means they have some CDMO exposure.

So it helps to distinguish:

• Primarily contract manufacturers with limited development work
• Pharma/API companies with some CDMO exposure
• Companies that are genuinely building a development-led CDMO/CRDMO platform

When you’re investing, you want to know which bucket you’re actually buying.

How I think about CDMO “tiers”

Once you understand the business model, it’s easier to think about companies in broad tiers based on capability and maturity. This isn’t about exact rankings; it’s a mental model to keep expectations realistic.

Tier 1: Established, scaled CDMO platforms

These are companies that have already shown they can:

• Take global pharma programs from development into commercial scale
• Meet stringent regulatory standards
• Convert development projects into commercial manufacturing
• Maintain relationships with big, repeat customers

Common traits:

• Deep process development capabilities
• Strong track record with global innovators
• Multiple commercial molecules in their portfolio
• Significant, ongoing capex tied to visible customer demand

Some also have exposure to newer, complex areas like peptides, biologics, or gene therapy, which could be important growth drivers as therapies like GLP-1s expand.

Tier 2: Challengers scaling up

Tier 2 companies usually have:

• Proven technical capabilities (often in a niche, like complex chemistry or fluorination)
• A growing CDMO or custom manufacturing segment
• Some commercial molecules, but at a smaller scale than Tier 1
• Active investment in new capacity and R&D

The story here is often about transition: moving from being a niche API or intermediate player to a more integrated CDMO platform. The upside can be meaningful if they execute well, but there’s usually more volatility in quarterly numbers and more execution risk.

Tier 3: Traditional manufacturers moving up the value chain

Tier 3 companies typically start with an established API or pharma manufacturing base and are now trying to:

• Add CDMO capabilities
• Win NCE (new chemical entity) projects
• Build peptide, biologics, or other specialty platforms
• Move from pure manufacturing to development-led work

They might talk about:

• Number of NCE programs under development
• Peptide or GLP-1-related capacity being built
• New R&D centers and specialized facilities

At this stage, the CDMO business is more of a future opportunity than a fully proven engine. A lot depends on whether current development programs actually make it to commercialization.

Why capex and pipelines are not guarantees

One of the big traps in hot themes like CDMO is assuming:

• Big capex = big future revenue
• Lots of development projects = lots of future commercial molecules
• One strong quarter = new normal

Reality is messier:

• Capacity can be built before demand fully materializes
• Development projects can fail in trials or get delayed
• Product mix and currency can make margins swing from quarter to quarter

So it’s important to track not just announcements, but actual progress:

• Are new facilities getting utilized?
• Are development projects moving into late-stage and commercial supply?
• Is revenue from CDMO growing in line with management’s own guidance?
• Are margins stabilizing at healthy levels, or are they spiky and one-off?

Valuation: the quiet risk in popular themes

Even if the business executes well, your returns depend heavily on what you pay.

In a hyped theme like CDMO, stock prices often bake in:

• Future capacity that isn’t yet fully utilized
• Future molecule launches that might slip or fail
• Future margin expansion that may or may not be sustainable

If reality comes in even slightly below those expectations, you can see valuation derating even while the company is still growing in absolute terms.

This is very similar to how investors think about other growth themes like dividend growth stocks or tech platforms. The story might be right, but if you overpay, the math can still work against you. If you’re curious about how to analyze this in another context, I walk through a similar idea in my guide to finding dividend growth stocks you can hold for the long term.

How to track a CDMO thesis over time

If you decide to invest in a CDMO stock, think of it as an ongoing research project, not a one-time decision. Some things worth tracking over time:

• Quarterly results: especially CDMO segment growth, if disclosed
• Customer additions: are they winning new innovators or deepening ties with existing ones?
• Project progression: how many molecules are moving from early to late-stage, and into commercial?
• Capacity utilization: are new plants and lines filling up?
• Capex vs. returns: is heavy investment starting to show up in revenue and margins?
• Management commentary: do they deliver on timelines and targets they’ve set in the past?

Ultimately, you’re not investing in “the CDMO theme.” You’re investing in a specific company, at a specific price, with a specific set of expectations already embedded in that price.

Bringing it back to your overall investing plan

CDMO stocks sit firmly in the “individual stock, sector-specific” bucket. They can play a role in a diversified portfolio, but they’re not a substitute for a solid core built around simple, broad-based investing.

If you’re still getting your foundation in place—things like emergency savings, retirement accounts, and basic index investing—it’s worth making sure those pieces are solid before leaning too hard into specialized themes. If you want a refresher on building that foundation, you might like my guide on using simple systems and tools to streamline your money decisions.

The CDMO opportunity, especially in markets like India, looks real and potentially large. But the edge comes from understanding the business model, being honest about where each company sits on the spectrum from manufacturer to true development partner, and being disciplined about price and expectations.

That’s how you move from chasing buzzwords to making thoughtful, long-term investing decisions.